NDAORAL-21TABLET
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DESOGEN (desogestrel; ethinyl estradiol) by Merck & Co. is clinical pharmacology pharmacodynamics combined oral contraceptives act by suppression of gonadotropins. Approved for pregnancy in women. First approved in 1992.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DESOGEN is a combined oral contraceptive containing desogestrel and ethinyl estradiol, approved by Merck & Co. in 1992. It prevents pregnancy primarily through suppression of gonadotropins and ovulation, with additional mechanisms including cervical mucus thickening and endometrial changes. The active metabolite 3-keto-desogestrel exhibits high progestational activity with minimal androgenicity.
LOE Approaching
This product is approaching loss of exclusivity with minimal current spending data, signaling a contracting team and shift toward generic management or portfolio consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Combined oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus, which increase the difficulty of sperm entry into the uterus,…
Worked on DESOGEN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.